Johnson & Johnson Reports Strong Q2 Earnings, Boosts Full-Year Forecast Amid Growth in Pharmaceuticals
Johnson & Johnson's second-quarter results exceeded Wall Street expectations, driven by strong sales from its immunology and cancer drugs, prompting the company to raise its full-year sales and profit forecasts.